Yahoo
NasdaqCM - Delayed Quote USD

FibroBiologics, Inc. (FBLG)

1.8100 +0.0500 (+2.84%)
At close: September 4 at 4:00:01 PM EDT
1.7841 -0.0259 (-1.43%)
After hours: September 4 at 7:56:47 PM EDT
Chart Range Bar
Loading chart for FBLG
  • Previous Close 1.7600
  • Open 1.7300
  • Bid 1.0000 x 700
  • Ask 1.4600 x 100
  • Day's Range 1.7100 - 1.9000
  • 52 Week Range 0.6200 - 12.4000
  • Volume 210,182
  • Avg. Volume 217,919
  • Market Cap (intraday) 12.051M
  • Beta (5Y Monthly) 1.67
  • PE Ratio (TTM) --
  • EPS (TTM) -5.1000
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 12.50

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

fibrobiologics.com

15

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

FBLG
59.78%
S&P 500 (^GSPC)
12.75%

1-Year Return

FBLG
84.76%
S&P 500 (^GSPC)
18.71%

3-Year Return

FBLG
99.70%
S&P 500 (^GSPC)
70.93%

5-Year Return

FBLG
99.70%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -4.12M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

6.00
12.50 Average
1.8100 Current
19.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/4/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 8 -> 6

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -95.77%

  • Return on Equity (ttm)

    -660.08%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -18.14M

  • Diluted EPS (ttm)

    -5.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.52M

  • Total Debt/Equity (mrq)

    31.54%

  • Levered Free Cash Flow (ttm)

    -8.37M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: